Contrast-enhanced ultrasound (CEUS) has evolved from the use of agitated saline to second generation bioengineered microbubbles designed to withstand insonation with limited destruction. While only one of these newer agents is approved by the Food and Drug Administration for use outside echocardiography, interventional radiologists are increasingly finding off-label uses for ultrasound contrast agents. Notably, these agents have an extremely benign safety profile with no hepatic or renal toxicities and no radiation exposure. Alongside diagnostic applications, CEUS has begun to develop its own niche within the realm of interventional oncology. Certainly, the characterization of focal solid organ lesions (such as hepatic and renal lesions) by CEUS has been an important development. However, interventional oncologists are finding that the dynamic and realtime information afforded by CEUS can improve biopsy guidance, ablation therapy, and provide early evidence of tumor viability after locoregional therapy. Even more novel uses of CEUS include lymph node mapping and sentinel lymph node localization. Critical areas of research still exist. The purpose of this article is to provide a narrative review of the emerging roles of CEUS in interventional oncology.
Since the 1960s with early use of agitated saline for cardiac and vascular ultrasound enhancement, the field of contrast-enhanced ultrasonography (CEUS) has grown tremendously [1] . CEUS has found diagnostic applications in echocardiography, solid organ investigation, vascular morphology, and extravascular interrogation (lymphatic, biliary, intra-cavitary) [2] . Established clinical guidelines exist in echocardiography and hepatic ultrasound with emerging literature advocating for guidelines in other diagnostic applications including renal and thyroid ultrasound [2, 3] .
Contrast-enhanced ultrasound relies on the inherent non-linear scatter of microbubble-based ultrasound contrast agents (UCA) [4] . Because tissues generally produce linear scatter at the transmit frequency (f 0 ), pulse inversion or other non-linear-based software can be used to suppress the surrounding tissue [4] . By detecting scatter at the harmonic (2 9 f 0 ), subharmonic (0.5 9 f 0 ) or superharmonic (n 9 f 0 ) levels, greater contrast-to-tissue signal ratio can be achieved [4] .
Real-time ultrasonography, cross-sectional imaging, and digital subtraction angiography/fluoroscopy are key tools in an interventional radiologist's arsenal. With an emergence of CEUS in diagnostic applications, the natural evolution of the technology is towards interventional practices [2] . The oncologic applications of CEUS are readily apparent as solid tumor malignancies can be defined by characteristic enhancement patterns and treatment response by changes in vascularity [3] . The purpose of this review is to highlight the various emerging roles of CEUS in interventional oncology.
Ultrasound contrast agents
A variety of UCA are now commercially available [1] . These agents are characterized by an outer stabilizing shell and inner gas core. Because of their size (1-6 uM, approximating the size of a red blood cell), these microbubbles are too large to extravasate from the blood stream into the interstitium [5] . This blood pooling characteristic makes these agents ideal for vascular and delayed vascular imaging. [5] The improved signal-tonoise ratio affords for improved lesion characterization. [1] First generation UCA used an air gas core [1] . These microbubbles were very fragile and short-lived because
Technical considerations
Adequate CEUS examination necessitates many of the same principals as standard ultrasound including patient positioning, probe selection, and careful attention to focal point and gain. However, additional considerations exist. Appropriate patient and technique selection per interventional procedure is paramount.
CEUS is best situated for targeted assessments rather than general examinations because of the need to examine entire contrast kinetics of the target. This can make select situations difficult-such as the cirrhotic liver where identification of specific nodules of concern by gray-scale may be difficult and obscured by a course heterogeneous hepatic window [12] . Additionally, because commercially available CEUS rely on superharmonics, penetration and imaging of deeper structures may be limited. CEUS is ''operator-dependent''-even more so than conventional ultrasound. In our practice, the radiologist accompanies the sonographer during the examination and requires active participation [13] . This is unlike CT or MRI and can be an obstacle to adoption in many institutions [13] .
Low mechanical index (MI) sonography should be utilized (< 0.3) to avoid bubble cavitation/destruction. This is important because we recommend performing CEUS in split-screen mode with gray-scale display alongside CEUS images for improved anatomic localization. Standard gray-scale sonography will destroy many of the bubbles without attention to manufacturer set MI. Like color and power Doppler, time-elapsed clips should be recorded through each phase of every lesion in question-the strength of CEUS is its ability to provide dynamic information.
Intravenous (IV) access is required for CEUS. We recommend at least a 20-gauge catheter to avoid inadvertent bubble destruction during administration. Generally, we recommend bolus dose administration (refer to package insert for maximum dose) followed by 5-10 mL normal saline flush for most applications. However, if quantitative enhancement analysis or extended examination is desired, an infusion may be utilized to provide consistent vascular opacification. Increasing the bolus dose should typically be avoided, particularly in deeper lesions, because this limits penetration. If re-examination is required, repeat injection may be performed (with attention to maximum dose per manufacturer guidelines) after existing microbubbles have been eliminated. This may take at least 5-10 min.
Focal lesion characterization
CEUS has shown to be a valuable decision-making adjunct to standard cross-sectional imaging in the diagnosis of focal solid organ tumors including liver and renal lesions. CEUS provides real-time imaging and parenchymal enhancement allowing for a stronger temporal understanding of lesion vascularity dynamics [2] . Additionally, because of their benign safety profile of UCA, examination may be repeated in cases of study inadequacy up to a maximum allowable dose per the agent [3] . For the interventional oncologist, CEUS is particularly salient in diagnostic dilemmas regarding focal hepatic and renal lesions, especially in patients with contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) contraindications such as low glomerular filtration rate (GFR), pacemakers, or claustrophobia [2, 3] .
Focal liver lesions
On CEUS, focal liver lesions can be characterized by the timing and pattern of enhancement at each of three phases of examination timed from the beginning of the infusion of contrast: arterial (10-45 s), portal (45-120 s), and late venous (120 s to bubble disappearance) [3] . This is similar to contrast-enhanced CT or MRI of focal liver lesions. These are summarized in Table 1 . Specifically, benign lesions tend to maintain enhancement through portal and late venous phases (with the exception of simple cysts which do not enhance in any phase) [3] . They can be differentiated by their patterns of enhancement [3] . Contrastingly, malignant lesions are characterized by variable arterial enhancement with notable portal and late venous phase washout [3] . In 2017, The American College of Radiology (ACR) has published a CEUS LI-RADS system to standardize the diagnosis of HCC using CEUS based on these characteristics [14] .
Clinical vignette: focal liver lesion
A contrast-enhanced CT scan performed of a 33-year-old female revealed an indeterminate hypodense 1.2-cm lesion in the left hepatic lobe. The patient was initially referred for ultrasound-guided biopsy of the lesion. After discussion with the referring team, CEUS of the liver lesion was first performed. The examination was performed using a bolus dose 0.2 mL Definity (N. Billerica, MA) as UCA. The examination revealed a 1.4 9 1.3 9 1.6 cm lesion with peripheral discontinuous globular enhancement (extending from the left of image towards the center of the lesion) in the arterial phase and no washout (Fig. 1) . The lesion was determined to be a hemangioma and biopsy was avoided.
Focal renal lesions
Similarly, CEUS has been shown to be valuable in the characterization of indeterminate renal lesions. Solid renal masses with enhancement and early washout are highly suggestive of malignancy (in the absence of macroscopic adipose tissue) [4, 15] . Additionally, enhancement of renal vein thrombus can suggest tumor thrombus (as opposed to bland thrombus) [2] . In cystic renal masses, CEUS features suggestive of malignancy include the presence of nodular/thick enhancing septations and heterogeneous patchy lesion enhancement [15] . Contrastingly, lack of enhancement or the presence of very thin poorly enhancing septations suggests against malignancy [15] . Supportive studies are currently being performed for the creation of a standardized system of diagnosis for renal cell carcinoma with a particular emphasis on the role of CEUS [15, 16] .
Clinical vignette: focal renal lesion
On non-contrast CT scan, an incidental 7.4 9 4.2 x 8.6 cm exophytic renal mass was detected in an 88-yearold male with chronic kidney disease ( Fig. 2A) . CT contrast agent was contraindicated due to patient's poor GFR. Instead, CEUS was performed using bolus dose 0.2 mL Definity (N. Billerica, MA) as UCA. The examination revealed 7.1 9 7.0 9 6.2 complex cystic lesion with no internal enhancement, consistent with a benign hemorrhagic or proteinaceous cyst (Fig. 2C) . Biopsy was avoided, and the patient was recommended for interval follow-up.
Image guidance for interventional procedures
CEUS can be useful in providing real-time procedural imaging guidance. Discrimination of viable, actively perfused areas of tumor from necrotic/cystic areas can be used to overcome biopsy-associated sampling error [2] . Additionally, immediate tumor perfusion analysis allows for real-time responsive feedback to thermal ablative therapies [17, 18] . The role of CEUS in lymph node interrogation is currently evolving with applications in sentinel and staging lymph node assessments [19] . Iso-/non-enhancement Hypo-/non-enhancement
Image guidance for percutaneous procedures
As stated, CEUS has shown the ability to improve image-guided percutaneous biopsies in a variety of solid organs. CEUS provides real-time perfusion imaging allowing for the interventional radiologist to more accurately target the actual pathology of the lesion rather than a cystic pocket or the necrotic core [2] . Utilizing CEUS, liver biopsy diagnostic accuracy in tumors can rise from as low as 87% to as high as 96%-100% [20, 21] . Additionally, CEUS has been used to guide biopsies in liver lesions not visible on gray-scale ultrasound [22] . CEUS has also shown value in renal and lung tumors [2, [23] [24] [25] . However, application to solid organ biopsy guidance is still in its infancy. Early comparative results are summarized in Table 2 . While early series have not shown any improvement in diagnostic accuracy or sensitivity with the use of CEUS in endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA) for pancreatic lesions, Sugimoto et al. 2015 described increased interventional efficiency with the use of CEUS-EUS-FNA compared with EUS-FNA (by percent of samples demonstrating sufficiency with a single needle pass, 60% vs. 25%, N = 20 vs. 20, P < 0.05) [26] .
Newer is CEUS to guide targeted prostate biopsies for prostate adenocarcinoma [2] . Because transrectal ultrasonography using gray-scale or power doppler ultrasound has shown to be poor predictors for identifying malignancy, interventional radiologists and urologists must perform thorough and systematic multi-core prostate biopsies of all regions [2, 27] . However, because of the increased micro-vascularity found in prostate cancer, nodular enhancement seen on CEUS may serve as a valuable guide [2, [28] [29] [30] . Centers are now performing randomized controlled trials assessing this potential for increasing relevant tissue sampling [28] . The performance of CEUS-guided biopsy compared with the multi-core systematic technique shows variable significance. Halpern et al. 2012 even reports increased detection rate of the multi-core systematic technique (39% vs. 26%, P < 0.001) [28] . However, after performing analysis per-core retrieved (rather than per patient examined), CEUS-guided biopsy appears to nearly ubiquitously demonstrate increased diagnostic yield (see Table 3 ). This suggests that routine detection rate may, in part, be supplemented simply by increased sampling [31] . Still, CEUS-guided biopsy in prostate cancer shows poor overall yields due to inadequate suppression of normal tissue enhancement or vas- cularity [28] . Attempts at chemical (such as 5a-reductase inhibitors) and technical (including subharmonic imaging, elastography, and multi-parametric or fusion imaging) discrimination from benign prostate tissue are currently at the forefront [28, 32] .
Clinical vignette: CEUS-assisted percutaneous biopsy
A contrast-enhanced CT demonstrated an enlarging 8 x 4 x 5 cm heterogeneously enhancing left flank mass in a 65-year-old male with a known history of melanoma (Fig. 3A) . Multiple ultrasound and CT-guided guided core needle biopsies of this lesion were performed at an outside institution, all showing only necrotic debris on pathology. Consequently, a CEUS-guided 18-gauge core needle biopsy was performed using a bolus dose 0.5 mL Definity (N. Billerica, MA) as UCA. The bolus dose was administered twice-first to delineate the lesion and a second time for real-time needle guidance. The enhancing portion of the lesion was targeted (Fig. 3C) to avoid necrotic elements of the mass. Pathology was consistent with metastatic melanoma and the patient was referred to the oncology service for further management.
Image guidance for thermal ablation therapies
Similarly, interventional oncologists can utilize CEUS for image guidance during thermal ablation because of its ability to delineate real-time tumor perfusion dynamics [33] . Pre-procedural CEUS allows for high fidelity treatment margin identification and the development of an precise volumetric map [2] . Additionally, intra-procedural CEUS can allow for accurate targeting for ablation [2] . Electrode placement during percutaneous thermo-ablative therapy can be difficult in lesions that are incompletely visualized on gray-scale sonography [34] . In patients with HCC poorly imaged by grayscale ultrasound selected for radiofrequency ablation, Minami et al. 2004 demonstrated complete tumor necrosis with a single session of treatment in 95.2% of the patients treated by CEUS guidance versus 32% in patients treated by gray-scale ultrasound guidance alone (N = 21 vs. 25) [35] . Finally, CEUS has shown immediate value in assessment of incomplete treatment (performed while the patient is still in the interventional suite)-with a reduction in up to 31% of patients requiring a second treatment [17, 18] .
Evaluation of lymph nodes
CEUS still appears to be limited (as gray-scale ultrasound) in differentiating malignant from benign lymph nodes [2] . On CEUS, tumor-involved lymph nodes may show a filling defect representing rarefication of nodal vessels by tumor invasion, but this finding is not invariable [36] . However, UCA injected peri-tumorally have been shown to distribute along adjacent lymphatics [31, 54] 60 vs. internal control (225 vs. 600) 22% (13%) 2 7 % (8.3%) P > 0.25 (P = 0.034) Mitterberger et al. [31, 55] 1776 vs. internal control (8880 vs. 17,760) 27% (10.8%) 2 3 % (5.1%) P < 0.001 (P < 0.001) Taverna et al. [31, 56] 100 vs. 100 29% 31% P = 0.3 Halpern et al. [28, 31] 272 vs. internal control (1237 vs. 3264) 26% (16.4%) 3 9 % (8.5%) P < 0.001 (P < 0.001) Zhao et al. [31, 57] 65 vs. internal control (44 vs in a fashion similar to standard blue dye and tracer methods for the identification of sentinel nodes [19] . Compared with the blue dye and tracer methods, CEUS allows for real-time tracking without the need for surgical dissection. CEUS-assisted preoperative wire localization of sentinel lymph nodes has been described [37] . This has value in the prognostication and treatment of cutaneous melanoma and breast cancer. However, this application is still largely experimental.
Early assessment of tumor response after locoregional treatment
Contrast-enhanced cross-sectional imaging is the traditional method of assessing tumor response after locoregional treatment of solid organ tumors. However, in addition to being cumbersome and limited intra-operatively (such as with cone beam CT), imaging is frequently delayed from between 1 week to up to several months after therapy to reduce obscuration of nodular peripheral tumor viability or recurrence by reactive hyperemia (and to reduce lipiodol artifact if CT is pursued). [38] [39] [40] This limits the potential for early intervention in patients harboring residual viable malignancy. CEUS may help to identify these early treatment failures and serve as an adjunct assessment in patients with contraindications to MRI or CT contrast (such as renal insufficiency) after locoregional therapy.
Tumor response: hypothermal ablative therapy
Hypothermal ablative therapy (cryoablation) mediates cellular destruction by repeated freeze-thaw-refreeze cycles induced by a needle-sized cryoprobe [41] . When utilized for renal cell carcinoma, contrast-enhanced CT may be delayed as late as 4 months after treatment to reduce false positives from post-ablation inflammation [4] . Following confirmation of effective therapy, variable surveillance protocols exist. However, many of these patients suffer from low GFR, and thus gadolinium and iodinated contrast are contraindicated. First described in 2005, early experience with CEUS in cryoablation suggests excellent concordance (with up to 100% sensitivity and between 90% and 100% specificity) with contrastenhanced cross-sectional imaging without renal toxicity or radiation [42] [43] [44] [45] . However, admittedly, available data for CEUS after cryoablation are still currently extremely limited and comprised primarily of case series and limited sample sizes. 
Clinical vignette: monitoring treatment effect after cryoablation
CT scan performed of a 74-year-old male revealed a 3.4-cm right renal lesion with enhancement concerning for renal cell carcinoma (Fig. 4A) . Due to the patient's medical comorbidities, the patient was deemed a poor surgical candidate and percutaneous cryotherapy was instead performed. A CEUS examination was performed 8 months later showing a post-ablation cavity without any nodular enhancing component, suggesting complete response to therapy (Fig. 4C ).
Tumor response: hyperthermal ablative therapy
Hyperthermal ablative therapies (such as microwave ablation) rely on heat produced by resistive tissue friction by needle-sized radiofrequency probes to cause cellular CT/MRI 1 month after treatment *Time after ablative therapy at which CEUS examination was performed destruction (and protein denaturation or even cellular vaporization) [41] . As noted earlier, CEUS has been used for immediate assessment of treatment effect to reduce the rates of incomplete radiofrequency ablation for HCC to as low as 6% after initial treatment [3, 46] . This has the potential of reducing the healthcare costs associated with retreatment [17] . Table 4 summarizes our current understanding regarding the performance of CEUS in treatment-monitoring after cryoablative and hyperthermal ablative therapies in renal and hepatic lesions. Early CEUS (performed within 24-h post-treatment) may have limited sensitivity to inadequate treatment (as low as 40%) due to difficulty in differentiating viable tumor from post-procedural reactive hyperemia and technical limitations (such as poor patient tolerance post-anesthesia and interposed bowel gas) [47] [48] [49] [50] . However, specificities between 98% and 100% suggest that early CEUS may still play a role in post-procedural survey. [47] [48] [49] Importantly, CEUS obtained at least one month after therapy has shown to be concordant with contrastenhanced cross-sectional imaging with sensitivities between 79% and 100% and specificities between 92.9% and 100% [43, 49] .
Tumor response: intra-arterial embolization therapy
Finally, intra-arterial embolization therapies such as trans-arterial chemoembolization (TACE) and trans-arterial radioembolization (TARE) have found a particular role in locally advanced HCC and as a bridge to hepatic transplantation [41] . As in thermal ablative therapies, cross-sectional imaging is obtained only after 4 weeks after therapy to minimize artifacts associated with inflammatory hyperemia and lipiodol (the latter for if CT is performed) [38, 39] . However, early findings suggest that CEUS can detect residual tumor viability and enhancement in as little as one week following treatment with strong concordance [39] . Notably, the literature is limited with regard to direct comparative studies evaluating CEUS verse contrast-enhanced cross-sectional imaging in patients with TACE. The literature is even sparser with regard to TARE. Table 5 summarizes the salient studies illustrating the performance of CEUS after TACE in HCC.
Clinical vignette: monitoring treatment effect after TACE
A CT scan obtained of a 65-year-old male with HCC shows a 2.8 9 2.6 9 2.5 cm segment VI lesion (LI-RADS 5) with arterial enhancement (Fig. 5A ) and brisk washout on delayed imaging. The patient underwent TACE with drug-eluting beads containing doxorubicin via the segment 6 branch of the right hepatic artery. CEUS performed one week after TACE shows partial tumor response with a small portion of the lesion still enhancing, favoring residual viable tumor (Fig. 5C ). This was later confirmed on follow-up MRI.
Conclusion
CEUS has gained significant momentum since its inception in the 1960s. CEUS is well positioned as a problemsolving tool for an interventional radiologist's diagnostic dilemmas. Newest applications include lesion targeting and treatment effect monitoring. Significant impetus exists for further clinical research and engineering innovation as novel roles continue to mature within interventional oncology.
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